HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Lowers Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has maintained a Buy rating on Halozyme Therapeutics (NASDAQ:HALO) but reduced the price target from $61 to $48.

January 18, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Halozyme Therapeutics' price target has been lowered from $61 to $48 by HC Wainwright & Co., although the Buy rating is maintained.
The reduction in price target may cause some investors to adjust their valuation models, potentially leading to short-term price fluctuations. However, the maintenance of a Buy rating suggests that the analyst still sees long-term value in the company, which could mitigate any negative reaction to the lower price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100